➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Dow
Mallinckrodt
Medtronic
Moodys

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IRINOTECAN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

505(b)(2) Clinical Trials for irinotecan hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00177853 ↗ Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer Terminated Pharmacia and Upjohn Phase 1 2006-12-01 The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex┬«) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.
New Combination NCT00177853 ↗ Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer Terminated University of Pittsburgh Phase 1 2006-12-01 The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex┬«) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.
New Combination NCT00215982 ↗ Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer Completed Roche Pharma AG Phase 2 2004-12-01 The purpose of this study is to find out how effective the new combination of the drugs Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Irinotecan (Camptosar) are against colon and rectal cancer. All three of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of colon or rectal cancer. This however is the first time that these three drugs have been combined in this schedule for the treatment of colon/rectal cancer.
New Combination NCT00215982 ↗ Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer Completed H. Lee Moffitt Cancer Center and Research Institute Phase 2 2004-12-01 The purpose of this study is to find out how effective the new combination of the drugs Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Irinotecan (Camptosar) are against colon and rectal cancer. All three of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of colon or rectal cancer. This however is the first time that these three drugs have been combined in this schedule for the treatment of colon/rectal cancer.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for irinotecan hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001495 ↗ A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1995-11-01 This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour drug-free intervals in patients with solid tumors in order to determine the maximum tolerated dose of this regimen.
NCT00002759 ↗ Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma Completed National Cancer Institute (NCI) Phase 1 1996-06-01 Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Cyclosporine and phenobarbital may enhance the effectiveness of irinotecan.
NCT00002902 ↗ Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1997-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
NCT00002902 ↗ Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Completed Abramson Cancer Center of the University of Pennsylvania Phase 1 1997-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for irinotecan hydrochloride

Condition Name

Condition Name for irinotecan hydrochloride
Intervention Trials
Colorectal Cancer 248
Metastatic Colorectal Cancer 126
Gastric Cancer 65
Pancreatic Cancer 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for irinotecan hydrochloride
Intervention Trials
Colorectal Neoplasms 530
Adenocarcinoma 154
Pancreatic Neoplasms 130
Stomach Neoplasms 106
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for irinotecan hydrochloride

Trials by Country

Trials by Country for irinotecan hydrochloride
Location Trials
United States 3,546
Canada 230
China 198
Japan 144
Italy 139
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for irinotecan hydrochloride
Location Trials
California 197
New York 190
Texas 145
Illinois 132
Ohio 126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for irinotecan hydrochloride

Clinical Trial Phase

Clinical Trial Phase for irinotecan hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 148
Phase 2/Phase 3 25
[disabled in preview] 744
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for irinotecan hydrochloride
Clinical Trial Phase Trials
Completed 519
Recruiting 294
Not yet recruiting 201
[disabled in preview] 110
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for irinotecan hydrochloride

Sponsor Name

Sponsor Name for irinotecan hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 281
Pfizer 48
Memorial Sloan Kettering Cancer Center 33
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for irinotecan hydrochloride
Sponsor Trials
Other 1290
Industry 610
NIH 289
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Moodys
Johnson and Johnson
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.